PLASMA BIOMARKER CASCADES IN NEURODEGENERATIVE DISEASES: MAPPING DIAGNOSTIC TRAJECTORIES AND ADDRESSING EXTRACEREBRAL CONFOUNDERS
Keywords:
liquid biopsy, neurodegeneration, plasma biomarkers, Alzheimer's disease, p-tau217, neurofilament light chain (NfL), GFAP, amyloid-betaAbstract
Background. The rapid aging of the global population is accompanied by a rising prevalence of neurodegenerative diseases, making their diagnosis at the preclinical stage a critical challenge. Conventional verification methods, including cerebrospinal fluid (CSF) analysis and positron emission tomography (PET), are constrained by invasiveness, high costs, and limited availability. The emergence of ultra-sensitive assay technologies has enabled the clinical application of peripheral blood "liquid biopsy", marking a paradigm shift in modern neurogeriatrics.
Aim. This review aims to systematize, compare, and critically analyze the diagnostic accuracy, pathophysiological significance, and clinical validation prospects of key plasma biomarkers (Aβ₄₂/Aβ₄₀, p-tau217, NfL, GFAP) in capturing the neurodegenerative cascade.
Main Content. The review provides a detailed analysis of the molecular profiles of modern peripheral blood biomarkers. It conducts a comparative analysis of their operational characteristics (AUC, sensitivity, specificity) against classical CSF analysis and neuroimaging via PET. Special emphasis is placed on the "gray zones" of the method, such as the impact of somatic comorbidities (chronic kidney disease, body mass index) on protein clearance and the challenge of international standardization across different laboratory platforms (SiMoA, IP-MS).
Conclusions. Plasma biomarkers (particularly p-tau217) demonstrate high diagnostic accuracy (AUC 0.90–0.96), comparable to invasive modalities. Integrating liquid biopsy as a first-line screening tool can fundamentally optimize early diagnosis algorithms and the longitudinal monitoring of targeted disease-modifying therapies.
References
1. Hansson O, Blennow K, Zetterberg H, et al. Preclinical trajectories of plasma p-tau217, GFAP, and neurofilament light chain in Alzheimer’s disease: a multi-cohort study. The Lancet Neurology. 2024;23(4):389-401. doi:10.1016/S1474-4422(24)00042-X.
2. Bateman RJ, Ashton NJ, Karikari TK, et al. Performance characteristics of plasma p-tau217 and Aβ42/Aβ40 mass spectrometry assays against tau and amyloid PET neuroimaging. JAMA Neurology. 2023;80(9):945-956. doi:10.1001/jamaneurol.2023.2114.
3. Blennow K, Zetterberg H. Blood biomarkers for Alzheimer's disease and related disorders: a paradigm shift in clinical neurogeriatrics. Annual Review of Biochemistry. 2025;94(1):215-238. doi:10.1146/annurev-biochem-052423-091102.
4. Schindler SE, Karikari TK, Barthélemy NR, et al. Effect of renal function and body mass index on the diagnostic accuracy of plasma p-tau217, p-tau181, and NfL. Neurology. 2024;102(11):e209412. doi:10.1212/WNL.0000000000209412.
5. Teunissen CE, Verberk IM, Thijssen EH, et al. Analytical cross-platform validation of digital immunoassays and mass spectrometry for blood-based neurodegenerative biomarkers: a joint consensus report. Alzheimer's & Dementia. 2025;21(3):512-524. doi:10.1002/alz.13511.
6. Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al. Plasma GFAP and p-tau217 as longitudinal tracking metrics for targeted anti-amyloid monoclonal antibody therapies. Nature Medicine. 2023;29(8):2014-2024. doi:10.1038/s41591-023-02443-3.
7. Benatar M, Wuu J, Turner MR, et al. Neurofilament light chain as a non-specific surrogate marker of axonal destruction in ALS and frontotemporal dementia: a longitudinal validation study. Brain. 2024;147(2):601-612. doi:10.1093/brain/awad322.


